- Case Report
- Open Access
Follicular bronchiolitis and lymphocytic interstitial pneumonia in a Japanese man
© Terada; licensee BioMed Central Ltd. 2011
- Received: 18 May 2011
- Accepted: 21 September 2011
- Published: 21 September 2011
A 44-year-old Japanese man consulted to our hospital because of cough and sputum. Chest-XP and CT revealed diffuse reticular opacities in both lungs.
A transbronchial lung biopsy (TBLB) showed a moderate infiltration of lymphocytes in the alveolar septae. He was diagnosed as interstitial pneumonia, and treated by drugs. One year later, his condition deteriolated, and a large open biopsy was performed. It showed a diffuse severe infiltration of lymphocytes in the alveolar walls and a few epithelioid granulomas. No bronchiolitis was seen.
Immunohistochemical study denied lymphocyte monoclonality, and he was diagnosed as lymphocytic interstitial pneumonia (LIP). He was treated by steroid.
Six months later, TBLB showed peribronchial lymphocyte infiltration. A large open biopsy also revealed a severe lymphocytic infiltration around the bronchioles, sparing alveolar wall lymphocytic infiltration. Immunohistochemical study denied malignant lymphoma. He was diagnosed as follicular bronchiolitis (FB). One year later, TBLB showed little lymphocytic infiltration in the alveolar walls as well as peribronchial walls. Two years later, his condition became worse, and TBLB showed features of LIP. Later, his condition was stationary for 6 years with mild lung opacities for 6 years. These findings show that LIP and FB are interchangeable and overlapping, and suggest that LIP and FB belong to the same spectrum of benign lymphoproliferative disorders of the lungs.
- follicular bronchitis
- lymphocytic interstitial pneumonia
Follicular bronchiolitis (FB) is a benign lymphoproliferative lung disease characterized by hyperplastic mucosa-associated lymphoid tissue present around the peribronchial spaces . Patients with FB are often associated with collagen vasculitis diseases, immunodeficiency state, hyperimmune state, and hereditary factors. Idiopathic FB is rare. Lymphocytic interstitial pneumonia (LIP) is also a benign lymphoproliferative lung disease characterized by severe lymphocytic infiltration of the alveolar septae . Patients with LIP are also often associated with collagen vascular diseases, immunological diseases, immunodeficiency diseases, lung infections, and drug induced diseases. When FB and LIP are pathologically diagnosed, exclusion of malignant lymphoma is mandatory . Herein reported is a case with benign lung lymphoproliferative diseases with 11 years follow-up.
Six months later, a TBLB showed peribronchial lymphocyte infiltration (Figure 2d). A large open biopsy also revealed severe lymphocytic proliferation around the bronchioles, sparing alveolar wall lymphocytic infiltration (Figures 2e and 2f). The lymphocytes did not show significant atypia. Germinal centers were scattered. The Immunohistochemical study was the same as the previous study and denied lymphocytic monoclonality (malignant lymphoma). Therefore, the lymphoid proliferation was thought to be mucosa-associated lymphoid hyperplasia. He was diagnosed as FB. One year later, TBLB showed little lymphocytic infiltration in the alveolar walls as well as peribronchial walls (Figure 2g). Two years later, his condition became worse, and a TBLB showed features of LIP (Figure 2h). Later, his condition was stationary for 6 years with mild lung opacities.
The author followed up a patient with lymphoproliferative disease of the lung for 11 years. In the two open lung biopsies, the lymphocytes appeared mature, and immunohistochemical studies showed that the lymphocytes had phenotypes of both B- and T cells. Light chain restriction was absent. P53 was negative, and Ki-67 labeling was low. Therefore, the current case was not malignant lymphoma including extranodal marginal B-cell lymphoma (MALT lymphoma). The patient condition was relatively even for 11 years, suggesting that the lung lesion was not malignant lymphoma.
Thus, the present case is benign lymphoproliferative disease. Benign lymphoproliferative diseases were classified into intrapulmonary lymph nodes, FB, LIP, nodular lymphoid hyperplasia (NLH), and Castleman's disease . The current case is obviously different from intrapulmonary lymph nodes and Castleman's disease (giant lymphoid hyperplasia). The present case is different from NLH, in which larger lymphoid nodules (0.6 cm -6 cm, mean 2.1 cm) were scattered in the lungs .
The first open biopsy of the present study is obviously LIP . It is not sarcoidosis, because LIP may show epithelioid granuloma . The second open biopsy was obviously FB . The last TBLB is suggestive for LIP. Therefore, the present case showed LIP →FB→ LIP histologies. The present patient did not show other diseases including collagen vascular diseases. Therefore, the FB and LIP in the present case were idiopathic, a very rare phenomenon. These findings show that LIP and FB are interchangeable and overlapping, and suggest that LIP and FB belong to the same spectrum of benign lymphoproliferative disorders of the lungs. Similar suggestion was reported elsewhere .
Written informed consent was obtained from the patient for publication of this case report and accompanying images.
- Travis WD, Galvin JR: Non-neoplastic pulmonary lymphoid lesions. Thorax. 2001, 56: 964-971. 10.1136/thorax.56.12.964.PubMed CentralView ArticlePubMedGoogle Scholar
- Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y: Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002, 52: 740-746. 10.1046/j.1440-1827.2002.01416.x.View ArticlePubMedGoogle Scholar
- Nocholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, Isaacson PG, Corrins B: Reactive pulmonary lymphoid disorders. Histopathology. 1995, 26: 405-412.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.